Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Nathan who wrote (5820)	3/9/1998 2:12:00 PM
From: Jenna	Respond to of 120523

CBMI... bought at 10 5/8 RESEARCH ALERT - Creative BioMolecules <CBMI.O> NEW YORK, March 9 (Reuters) - Salomon Smith Barney said on Monday it started coverage on shares of Creative BioMolecules Inc with a buy rating and 12-month $15per share price target. -- Company is forecast to be first to market with an important new class of drugs for bone repair. -- "OP-1 is forecast to be the first biotechnology drug approved for treatment of bone fractures," analyst FranklinBerger said in a research note. -- Anticipated release f OP-1 Phase III clinical trial on March 20 at an orthopedics conference is defining event for company.